Lurbinectedin is a chemotherapy drug used to treat various types of cancer, including small cell lung cancer and ovarian cancer. According to Drug Patent Watch [1], the success rates of lurbinectedin therapy are not available. However, a study published in the Journal of Clinical Oncology [2] reported that lurbinectedin showed promising results in treating patients with relapsed small cell lung cancer, with a 35% overall response rate. Another study published in Cancer Science [3] found that lurbinectedin was effective in inhibiting the growth of ovarian cancer cells in vitro and in vivo. However, more research is needed to determine the overall success rates of lurbinectedin therapy.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.14464